BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals

 BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo,
                    MiMedx Group, Keryx Biopharmaceuticals

PR Newswire

CORAL SPRINGS, Florida, July 18, 2013

CORAL SPRINGS, Florida, July 18, 2013 /PRNewswire/ -- issues market news updates for today's active biotech
companies: Alliqua, Inc. (OTCQB: ALQA), Transition Therapeutics Inc. (NASDAQ:
TTHI), Organovo Holdings, Inc. (NYSE: ONVO), MiMedx Group, Inc. (NASDAQ:
MDXG), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)

Alliqua, Inc. (OTCQB: ALQA) Headline: Alliqua's SilverSeal Dressing Shown to
Improve Surgical Wound Outcomes in Clinical Study. ALQA today announced the
results from a post-marketing study to assess surgical wound outcomes in
patients who have undergone foot and ankle surgery. In this study, Alliqua's
SilverSealĀ® dressing was shown to have a lower incidence of incision
complications, including infection, and a greater reduction in scar length
compared to standard petroleum-based dressing. Study results are being
presented at the annual meeting of the American Orthopaedic Foot & Ankle
Society, which is being held in Hollywood, Florida July 17-20. Stephen A.
Brigido, DPM, director of the foot and ankle fellowship at the Coordinated
Health Foot and Ankle Center and a primary investigator in the study, stated,
"The results from this study are consistent with our preliminary findings
reported earlier this year and indicate SilverSeal has potential to not only
improve post-surgical incision healing but to reduce healthcare expenditures
related to incision complications." To read the entire press release, please
go to

FNM Market News: Wound Dressing Industry is Expected to Reach USD 6,012.4
Million Globally in 2017: Transparency Market Research - According to a new
market report published by Transparency Market Research
( "Wound Dressing Market - Global
Scenario, Trends, Industry Analysis, Size, Share & Forecast 2011 - 2017," the
global wound dressing market was worth USD 4,410.5 million in 2011 and is
expected to reach USD 6,012.4 million in 2017, growing at a CAGR of 5.3% from
2011 to 2017. In the overall global market, the U.S. is expected to maintain
its lead position in terms of revenue till 2017. The U.S. is expected to enjoy
34.6% of global wound dressing market revenue share in 2017 followed by
Europe. Browse the full report at

Transition Therapeutics Inc. (TTHI) announced that the US Food and Drug
Administration (FDA) has granted Fast Track Designation to the development
program for ELND005 which was submitted for the treatment of Neuropsychiatric
Symptoms (NPS) in Alzheimer's disease (AD). The FDA concluded that the
development program for ELND005 for the treatment of NPS in AD meets their
criteria for Fast Track Designation. Transition's licensing partner, Elan
Corporation, plc ("Elan"), is responsible for all development and
commercialization activities and costs of ELND005.

Organovo Holdings, Inc. (ONVO) develops three-dimensional (3D) bioprinting
technology for creating functional human tissues on demand for research and
medical applications. The company's 3D NovoGen bioprinting technology works
across various tissue and cell types, and allows for the placement of cells in
desired patterns. Organovo rang the opening bell on the New York Stock
Exchange (NYSE) this week as ONVO shares began trading on the NYSE on
Thursday, July 11, 2013, after qualifying as an NYSE MKT listing company.
"Organovo is proud to ring the opening bell on behalf of our employees,
investors and all of our supporters, in recognition of our recent uplisting to
the New York Stock Exchange. This milestone is another important step forward
for the company in our mission to advance the impact of 3D bioprinting in
changing the shape of medical research and practice," said Keith Murphy,
president and chief executive officer of Organovo Holdings, Inc. "We found
NYSE to have made an unparalleled commitment to providing a fertile platform
for growth to early stage biotechnology companies, and we look forward to a
great future on the exchange."

MiMedx Group, Inc. (MDXG), an integrated developer, manufacturer and marketer
of patent protected regenerative biomaterials and bioimplants processed from
human amniotic membrane, announced this week that the Company will slightly
exceed the $13.5 million high end of its previously communicated revenue range
for the second quarter of 2013. The Company's second quarter of 2013 revenue
represents an increase of greater than 175% over second quarter of 2012
revenue, and for the six months ended June 30, 2013, MiMedx revenue increased
by more than 190% over its revenue for the first six months of 2012. The
Company reported that the second quarter of 2013 marks the 7th consecutive
quarter in which MiMedx has met or exceeded its revenue guidance.

Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company, focuses on
the acquisition, development, and commercialization of pharmaceutical products
for the treatment of renal disease in the United States. It is developing
Zerenex (ferric citrate), an oral, ferric iron-based compound that has the
capacity to bind to phosphate in the gastrointestinal tract and form
non-absorbable complexes. The company has completed a Phase III clinical
program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with end-stage renal disease on dialysis. KERX closed up
3.15% on Wednesday on over 2.6Mil shares traded.

FinancialNewsMedia.comis leading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visithttp://www.financialnewsmedia.comfor more
details. Get an edge on the market with ourPremium News Alertsthat are FREE
for a limited time at Follow us on

DISCLAIMER:FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels.FNMG is NOT affiliated in any manner
with any company mentioned herein.FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security.FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities.The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material.All readers are strongly urged to perform research and due diligence
on their own and consult a licensed financial professional before considering
any level of investing in stocks. The companies that are discussed in this
release may or may not have approved the statements made in this release. FNMG
is not liable for any investment decisions by its readers or
subscribers.Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1(954)345-0611

Press spacebar to pause and continue. Press esc to stop.